Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
First-in-human results of terbium-161[ <sup>161</sup> Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.
James Buteau, Louise Kostos, Price Jackson, Lachlan McIntosh, Ramin Alipour, Timothy Akhurst, Michal Eifer, Brittany Emmerson, Mohammad B. Haskali, Kerry Jewell, Raghava Kashyap, Grace Kong, Declan G. Murphy, Aravind S. Ravi Kumar, Javad Saghebi, Shahneen Sandhu, Ben Tran, Jing Xie, Arun Azad, Michael S. Hofman (2025). First-in-human results of terbium-161[ <sup>161</sup> Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.. , 43(16_suppl), DOI: https://doi.org/10.1200/jco.2025.43.16_suppl.5010.
Article151 days agoPrognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials
Raghava Kashyap, James Buteau, Mathias Bressel, Michal Eifer, Neeraja Bollampally, Price Jackson, Lachlan McIntosh, Shahneen Sandhu, Michael S. Hofman (2025). Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. , DOI: https://doi.org/10.2967/jnumed.125.269640.
Article151 days agoPrognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials
Raghava Kashyap, James Buteau, Mathias Bressel, Michal Eifer, Neeraja Bollampally, Price Jackson, Lachlan McIntosh, Shahneen Sandhu, Michael S. Hofman (2025). Prognostic Value of Posttherapy SPECT/CT for Overall Survival in Patients Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. , DOI: https://doi.org/10.2967/jnumed.125.269640.
Article151 days agoFirst-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study
James Buteau, Louise Kostos, Price Jackson, Jing Xie, Mohammad B. Haskali, Ramin Alipour, Lachlan E McIntosh, Brittany Emmerson, Lisa L. MacFarlane, Claire A Martin, Joanna Chan, Sarah E. Williams, Kerry Jewell, Michal Eifer, A. Hamilton, W HARRIS, Tim Akhurst, Lewis Au, Anthony Cardin, Luc Furic, Raghava Kashyap, Grace Kong, Aravind S. Ravi Kumar, Declan G. Murphy, Rajeev Ravi, Javad Saghebi, Shahneen Sandhu, Ben Tran, Arun Azad, Michael S. Hofman (2025). First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study. , DOI: https://doi.org/10.1016/s1470-2045(25)00332-8.
Article151 days agoClinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&T
James Buteau, Louise Kostos, Ramin Alipour, Price Jackson, Lachlan McInstosh, Brittany Emmerson, Mohammad B. Haskali, Jing Xie, Elizabeth Medhurst, Rajeev Ravi, Brian D. Gonzalez, Heidi Fettke, Benjamin J. Blyth, Luc Furic, Katie L. Owen, Shahneen Sandhu, Declan G. Murphy, Arun Azad, Michael S. Hofman (2024). Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [<sup>161</sup>Tb]Tb-PSMA-I&T. , 65(8), DOI: https://doi.org/10.2967/jnumed.124.267650.
Article151 days ago